acetazolamide has been researched along with Retinal Diseases in 18 studies
Acetazolamide: One of the CARBONIC ANHYDRASE INHIBITORS that is sometimes effective against absence seizures. It is sometimes useful also as an adjunct in the treatment of tonic-clonic, myoclonic, and atonic seizures, particularly in women whose seizures occur or are exacerbated at specific times in the menstrual cycle. However, its usefulness is transient often because of rapid development of tolerance. Its antiepileptic effect may be due to its inhibitory effect on brain carbonic anhydrase, which leads to an increased transneuronal chloride gradient, increased chloride current, and increased inhibition. (From Smith and Reynard, Textbook of Pharmacology, 1991, p337)
Retinal Diseases: Diseases involving the RETINA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thirty patients with cystoid macular oedema secondary to chronic iridocyclitis were enrolled in a two period, prospective, randomised, double masked, crossover study that compared sustained release acetazolamide (500 mg twice a day) with a placebo to measure the effects on the reduction of cystoid macular oedema and improvement of visual acuity." | 9.07 | Reduction of macular oedema by acetazolamide in patients with chronic iridocyclitis: a randomised prospective crossover study. ( Cross, A; Farber, MD; Jennings, TJ; Lam, S; Rusin, MM; Tessler, HH, 1994) |
| "Hydroxychloroquine (HCQ) retinopathy can accompany other retinal complications such as cystoid macular edema (CME), which leads to central visual loss." | 7.85 | The effect of oral acetazolamide on cystoid macular edema in hydroxychloroquine retinopathy: a case report. ( Ahn, SJ; Hong, EH; Lee, BR; Lim, HW, 2017) |
| "The therapeutic effect of long-term treatment with acetazolamide (from 3 weeks to 16 months) of seven patients with retinitis pigmentosa was studied." | 7.68 | Long-term treatment of retinitis pigmentosa with acetazolamide. A pilot study. ( Aschero, M; Orzalesi, N; Pierrottet, C; Porta, A, 1993) |
| "Treatment with acetazolamide, at a dosage of 0." | 5.28 | [Serous retinal detachment. Value of acetazolamide]. ( Gonzalez, C, 1992) |
| "Thirty patients with cystoid macular oedema secondary to chronic iridocyclitis were enrolled in a two period, prospective, randomised, double masked, crossover study that compared sustained release acetazolamide (500 mg twice a day) with a placebo to measure the effects on the reduction of cystoid macular oedema and improvement of visual acuity." | 5.07 | Reduction of macular oedema by acetazolamide in patients with chronic iridocyclitis: a randomised prospective crossover study. ( Cross, A; Farber, MD; Jennings, TJ; Lam, S; Rusin, MM; Tessler, HH, 1994) |
| "Hydroxychloroquine (HCQ) retinopathy can accompany other retinal complications such as cystoid macular edema (CME), which leads to central visual loss." | 3.85 | The effect of oral acetazolamide on cystoid macular edema in hydroxychloroquine retinopathy: a case report. ( Ahn, SJ; Hong, EH; Lee, BR; Lim, HW, 2017) |
| "After 7 months of treatment for bilateral panuveitis with topical steroid and tropicamide, the patient developed a thin, transparent membrane arising on the lens surface in the right eye." | 3.70 | True exfoliation of the lens capsule following uveitis. ( Miyagawa, A; Yamamoto, N, 2000) |
| "The therapeutic effect of long-term treatment with acetazolamide (from 3 weeks to 16 months) of seven patients with retinitis pigmentosa was studied." | 3.68 | Long-term treatment of retinitis pigmentosa with acetazolamide. A pilot study. ( Aschero, M; Orzalesi, N; Pierrottet, C; Porta, A, 1993) |
| "Acetazolamide treatment for CSR shortens the time for subjective and objective clinical resolution, but has no effect on either final visual acuity or recurrence rate of the disease." | 2.70 | Acetazolamide for central serous retinopathy. ( Beiran, I; Miller, B; Ophir, A; Pikkel, J, 2002) |
| "Acetazolamide treatment resulted in oedema resolution and improvement in visual function, and can be considered a therapeutic option for other patients with Bietti dystrophy who develop cystoid macular oedema." | 1.40 | Acetazolamide for cystoid macular oedema in Bietti crystalline retinal dystrophy. ( Broadhead, GK; Chang, AA, 2014) |
| "Treatment with acetazolamide, at a dosage of 0." | 1.28 | [Serous retinal detachment. Value of acetazolamide]. ( Gonzalez, C, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (11.11) | 18.7374 |
| 1990's | 6 (33.33) | 18.2507 |
| 2000's | 5 (27.78) | 29.6817 |
| 2010's | 5 (27.78) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hong, EH | 1 |
| Ahn, SJ | 1 |
| Lim, HW | 1 |
| Lee, BR | 1 |
| Abaloun, Y | 1 |
| Omari, A | 1 |
| Broadhead, GK | 1 |
| Chang, AA | 1 |
| Dot, C | 1 |
| El Chehab, H | 1 |
| Russo, A | 1 |
| Agard, E | 1 |
| Plant, T | 1 |
| Aref-Adib, G | 1 |
| Romano, MR | 1 |
| Vinciguerra, R | 1 |
| Randazzo, A | 1 |
| Vinciguerra, P | 1 |
| Pikkel, J | 1 |
| Beiran, I | 1 |
| Ophir, A | 1 |
| Miller, B | 1 |
| Lois, N | 1 |
| White, M | 1 |
| Sauvé, Y | 1 |
| Karan, G | 1 |
| Yang, Z | 1 |
| Li, C | 1 |
| Hu, J | 1 |
| Zhang, K | 1 |
| Farber, MD | 1 |
| Lam, S | 1 |
| Tessler, HH | 1 |
| Jennings, TJ | 1 |
| Cross, A | 1 |
| Rusin, MM | 1 |
| Orzalesi, N | 1 |
| Pierrottet, C | 1 |
| Porta, A | 1 |
| Aschero, M | 1 |
| Shirao, Y | 1 |
| Hammond, CJ | 1 |
| Chauhan, DS | 1 |
| Stanford, MS | 1 |
| Yamamoto, N | 1 |
| Miyagawa, A | 1 |
| Yonemura, D | 1 |
| Kawasaki, K | 1 |
| Gonzalez, C | 1 |
| Weene, LE | 1 |
| Perkins, SA | 1 |
| Magargal, LE | 1 |
| Augsburger, JJ | 1 |
| Sanborn, GE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Short-Term Oral Mifepristone for Central Serous Chorioretinopathy. A Placebo-controlled Dose Ranging Study of Mifepristone in the Treatment of CSC (STOMP-CSC)[NCT02354170] | Phase 2 | 16 participants (Actual) | Interventional | 2015-01-31 | Completed | ||
| Treatment of Macular Oedema in Patients With Hereditary Retinal Dystrophies by Applying the Micropulsed Subthreshold Laser[NCT05976139] | 10 participants (Anticipated) | Interventional | 2023-09-06 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for acetazolamide and Retinal Diseases
| Article | Year |
|---|---|
[Ocular hypertension after intravitreal steroid injections: Clinical update as of 2015].
Topics: Acetazolamide; Adrenal Cortex Hormones; Adult; Animals; Child; Delayed-Action Preparations; Dexameth | 2015 |
Travelling to new heights: practical high altitude medicine.
Topics: Acclimatization; Acetazolamide; Acute Disease; Altitude; Altitude Sickness; Brain Edema; Cold Temper | 2008 |
[Current aspects in electrooculography].
Topics: Acetazolamide; Electrooculography; Fructose; Humans; Mannitol; Osmotic Pressure; Pigment Epithelium | 1997 |
2 trials available for acetazolamide and Retinal Diseases
| Article | Year |
|---|---|
Acetazolamide for central serous retinopathy.
Topics: Acetazolamide; Adult; Carbonic Anhydrase Inhibitors; Exudates and Transudates; Female; Humans; Male; | 2002 |
Reduction of macular oedema by acetazolamide in patients with chronic iridocyclitis: a randomised prospective crossover study.
Topics: Acetazolamide; Adult; Age Factors; Aged; Chronic Disease; Delayed-Action Preparations; Double-Blind | 1994 |
13 other studies available for acetazolamide and Retinal Diseases
| Article | Year |
|---|---|
The effect of oral acetazolamide on cystoid macular edema in hydroxychloroquine retinopathy: a case report.
Topics: Acetazolamide; Administration, Oral; Antirheumatic Agents; Carbonic Anhydrase Inhibitors; Dose-Respo | 2017 |
[Diffuse retinal epitheliopathy].
Topics: Acetazolamide; Carbonic Anhydrase Inhibitors; Fluorescein Angiography; Humans; Male; Middle Aged; Re | 2017 |
Acetazolamide for cystoid macular oedema in Bietti crystalline retinal dystrophy.
Topics: Acetazolamide; Administration, Oral; Adult; Corneal Dystrophies, Hereditary; Diuretics; Humans; Macu | 2014 |
Management of cyclodialysis cleft associated to hypotonic maculopathy.
Topics: Acetazolamide; Adolescent; Antihypertensive Agents; Ciliary Body; Clonidine; Cloprostenol; Combined | 2013 |
Acitretin-associated maculopathy.
Topics: Acetazolamide; Acitretin; Adult; Diuretics; Fluorescein Angiography; Humans; Keratolytic Agents; Mac | 2004 |
Treatment with carbonic anhydrase inhibitors depresses electroretinogram responsiveness in mice.
Topics: Acetazolamide; Animals; Carbonic Anhydrase Inhibitors; Carbonic Anhydrases; Disease Models, Animal; | 2006 |
Long-term treatment of retinitis pigmentosa with acetazolamide. A pilot study.
Topics: Acetazolamide; Adult; Drug Administration Schedule; Edema; Female; Fluorescein Angiography; Fundus O | 1993 |
Pulmonary hypertension and diffuse macular edema responsive to acetazolamide.
Topics: Acetazolamide; Adult; Blood Pressure; Edema; Female; Fluorescein Angiography; Fundus Oculi; Humans; | 1998 |
True exfoliation of the lens capsule following uveitis.
Topics: Acetazolamide; Aged; Betamethasone; Drug Therapy, Combination; Exfoliation Syndrome; Female; Humans; | 2000 |
New approaches to ophthalmic electrodiagnosis by retinal oscillatory potential, drug-induced responses from retinal pigment epithelium and cone potential.
Topics: Acetazolamide; Adolescent; Adult; Animals; Child; Color Vision Defects; Diabetic Retinopathy; Electr | 1979 |
[Serous retinal detachment. Value of acetazolamide].
Topics: Acetazolamide; Aging; Drug Evaluation; Female; Fluorescein Angiography; Humans; Macular Degeneration | 1992 |
Cystoid macular edema after scleral buckling responsive to acetazolamide.
Topics: Acetazolamide; Cell Membrane; Fundus Oculi; Humans; Macular Edema; Male; Middle Aged; Postoperative | 1992 |
The idling retina: reversible visual loss in central retinal artery obstruction.
Topics: Acetazolamide; Aged; Aspirin; Dipyridamole; Humans; Male; Retinal Artery; Retinal Diseases; Vision, | 1987 |